Fluorescein angiography in patients undergoing hemodialysis

• Published in: Journal of Japanese Society for Dialysis Therapy Vol. 26; no. 3; pp. 319 - 322
• Main Authors: Kishimoto, Taketoshi, Yamamoto, Mitsuhiro, Maekawa, Masanobu, Umeda, Masaru, Iwata, Hiroyuki, Izumi, Nobuhide, Yasumoto, Ryouji
• Format: Journal Article
• Language: Japanese
• Published: The Japanese Society for Dialysis Therapy 1993
• Subjects: Fluorescein angiography; hemodialysis
• ISSN: 0911-5889; 1884-6211
• DOI: 10.4009/jsdt1985.26.319

Fluorescein angiography is one of the most important tools in diagnosing retinal-choroidal diseases, and sodium fluorescein (NaFI) is widely used as a contrast medium. In the present study, we examined the pharmacokinetics of NaFI in patients undergoing hemodialysis (HD). NaFI, 500mg, was injected into 4 HD patients with ophthalmological complications, and HD was started immediately after fluorescein angiography had been completed. Changes in plasma concentrations and clearance of NafI were studied using a spectrophotometer, and the following results were obtained. Four hours after initiating HD treatment, the plasma concentration of NaFI had decreased to 17.5% of the initial concentration. The in-vivo clearance of NaFI during HD was 35.51±13.90ml/min (Mean±SD). The half life of NaFI in HD patients on a day without dialysis was extremely prolonged compared to those in non-dialyzed patients. Because of these results, together with the relatively good dialysability of NaFI, immediate HD after fluorescent angiography should be considered for the removal of residual contrast medium.